NCT04812977CompletedNot Applicable
Comparison of Intravitreal Bevacizumab and Triamcinolone Acetonide With Intravitreal Bevacizumab Alone in Macular Edema Secondary to Central Retinal Vein Occlusion
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hayatabad Medical Complex
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Visual Acuity
Study Overview
Brief Summary
To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.
Exclusion Criteria
- •previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.
Arms & Interventions
Group A
Experimental
A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
Intervention: Group A (Drug)
Group B
Active Comparator
Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
Intervention: Group A (Drug)
Outcomes
Primary Outcomes
Visual Acuity
Time Frame: Baseline and 6 months
Change in visual acuity
Secondary Outcomes
- Central Foveal Thickness(Baseline and 6 months)
Investigators
Yousaf Jamal Mahsood
Dr.
Hayatabad Medical Complex
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Comparison of Intravitreal Bevacizumab and Triamcinolone with Placebo in Acute Nonarteritic Anterior Ischemic Optic NeuropathyAnterior Ischemic of Optic Nerve.Disorders of optic nerve, not elsewhere classifiedIRCT1138901221180N13Ophthalmic Research Center16
Unknown
Phase 3
Effect of Intravitreal Bevacizumab on Clinically Significant Macular EdemaDiabetic Macular EdemaNCT00370669Shahid Beheshti University of Medical Sciences150
Unknown
Phase 3
Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical TrialDiabetic Macular EdemaNCT00370422Shahid Beheshti University of Medical Sciences
Completed
Not Applicable
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor VisionCentral Retinal Vein Occlusion With 20/200 or Worse Visual AcuityNCT01053858Hallym University Medical Center38
Unknown
Phase 3
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMDNeovascular Age-Related Macular DegenerationNCT00370370Shahid Beheshti University of Medical Sciences